Astellas Sales Drop 0.9% due to LLP Sell-Off, Japan Biz Hit by Generic Entry

Astellas Pharma’s full year group sales decreased 0.9% to 1.3 trillion yen in the year ended March 2018, impacted by the transfer of its global dermatological business to Denmark-based LEO Pharma A/S in April 2016, along with its long-listed products...read more